Innohep Possibly Unsafe For Elderly Patients: FDA

Law360, New York (December 3, 2008, 12:00 AM EST) -- The U.S. Food and Drug Administration has issued an alert for blood-clot medication Innohep, urging manufacturer LEO Pharma AS to update the drug’s warning labels to reflect mortality risks for patients over age 70.

The notice, released on Tuesday, cites the results of an ongoing study that found that Innohep increased the risk of mortality in patients aged 70 and above when compared with another formulation of heparin.

Innohep, also marketed as tinzaparin, is a type of heparin manufactured by Denmark-based LEO and marketed in the...
To view the full article, register now.